INCR
Intercure·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 0
Bullish Abandoned Baby
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About INCR
Intercure Ltd.
A leading, profitable, and fastest growing cannabis company outside of North America
Consumer Goods Distribution and Retail
11/20/1994
09/01/2021
NASDAQ Stock Exchange
330
12-31
Common stock
85 Medinat ha-Yehudim Street, Herzliya, 4676670, Israel
Focus on the production, manufacture, export and distribution of pharmaceutical-grade cannabis and medical cannabis products.
Intercure Ltd., an Israeli public company, was incorporated on November 20, 1994 under the Israeli Companies Law. One of the company's businesses focuses on the production (including breeding, nurturing, importing and processing), manufacturing, export and distribution of pharmaceutical-grade cannabis and medical cannabis products. Another business focus of the company is to build and operate specialized pharmacies to distribute pharmaceutical-grade cannabis under the "Givol" brand, including a "Cookies" brand location. In addition, Cannolam is seeking to establish a distribution network for recreational cannabis and cannabis products across Israel.
Company Financials
EPS
INCR has released its 2023 Q2 earnings. EPS was reported at 0.03, versus the expected 0.05, missing expectations. The chart below visualizes how INCR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
INCR has released its 2023 Q2 earnings report, with revenue of 27.69M, reflecting a YoY change of 1.71%, and net profit of 1.01M, showing a YoY change of -77.23%. The Sankey diagram below clearly presents INCR's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
